| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg |
201 |
188 |
$442K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,706 |
3,794 |
$399K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
2,216 |
1,634 |
$316K |
| 96401 |
|
807 |
430 |
$138K |
| 96415 |
|
874 |
699 |
$51K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
206 |
177 |
$29K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
493 |
373 |
$28K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
105 |
99 |
$17K |
| J0897 |
Injection, denosumab, 1 mg |
339 |
208 |
$16K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
451 |
351 |
$10K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
157 |
121 |
$3K |
| 99215 |
Prolong outpt/office vis |
17 |
12 |
$2K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
20 |
14 |
$13.84 |